サマリー

ブラジルのヒトインスリン製剤市場 2024-2028
ブラジルのヒトインスリン製剤市場は2023〜2028年に1億8176万米ドル成長し、予測期間中のCAGRは6.5%で加速すると予測されます。当レポートでは、ブラジルのヒトインスリン製剤市場について、市場規模や予測、動向、成長促進要因、課題などの全体的な分析に加え、約25のベンダーを網羅したベンダー分析も掲載しています。
現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。ブラジルの糖尿病有病率の上昇、ブラジルの人口動態の変遷、インスリン療法に対する意識の高まりが市場を牽引しています。
Technavio社の予測では、ブラジルのヒトインスリン製剤市場は以下のように分類されます：
製品別
- 基礎インスリンアナログ
- NPH（中性プロタミン製剤）
用途別
- I型糖尿病
- II型糖尿病
販売チャネル別
- 小売
- 病院
本調査では、糖尿病治療におけるバイオシミラーの登場が、今後数年間のブラジルのヒトインスリン製剤市場の成長を牽引する主要因のひとつであると分析している。また、ベンダーによる取り組みやヒトインスリン製剤の技術的進歩の増加は、市場の大きな需要につながる。
この調査レポートは、ブラジルのヒトインスリン製剤市場を分析・予測し、以下のてこ入れを行います：
- ブラジルのヒトインスリン製剤市場規模
- ヒトインスリン製剤のブラジル市場予測
- ブラジルのヒトインスリン製剤市場産業分析
強固なベンダー分析は、クライアントが市場での地位を向上させるために設計されており、これに沿って、本レポートでは、Becton Dickinson and Co.、Biocon Ltd.、Biomm、Eli Lilly and Co.、Empreendimentos Pague Menos SA、Gulf Pharmaceutical Industries、MannKind Corp.、Medtronic Plc、Merck and Co.Inc.、Novartis AG、Novo Nordisk AS、Sanofi SA、Wockhardt Ltd.。また、ブラジルのヒトインスリン製剤市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。
本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートには、主要ベンダーの分析に加え、包括的な市場およびベンダーランドスケープが含まれています。本レポートの詳細については、https://www.technavio.com/report/human-insulin-drugs-market-industry-in-brazil-analysis をご覧ください。
当出版社では、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、要約する方法で、市場の詳細なイメージを提示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

ページTOPに戻る

目次

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary - Chart on Market Overview
o Exhibit 02: Executive Summary - Data Table on Market Overview
o Exhibit 03: Executive Summary - Chart on Country Market Characteristics
o Exhibit 04: Executive Summary - Chart on Market Segmentation by Product
o Exhibit 05: Executive Summary - Chart on Market Segmentation by Application
o Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
o Exhibit 07: Executive Summary - Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 08: Parent market
o Exhibit 09: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 10: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 11: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 12: Chart on Brazil - Market size and forecast 2023-2028 ($ million)
o Exhibit 13: Data Table on Brazil - Market size and forecast 2023-2028 ($ million)
o Exhibit 14: Chart on Brazil: Year-over-year growth 2023-2028 (%)
o Exhibit 15: Data Table on Brazil: Year-over-year growth 2023-2028 (%)
• 4 Historic Market Size
o 4.1 Human insulin drugs market in Brazil 2018 - 2022
o Exhibit 16: Historic Market Size - Data Table on human insulin drugs market in Brazil 2018 - 2022 ($ million)
o 4.2 Product Segment Analysis 2018 - 2022
o Exhibit 17: Historic Market Size - Product Segment 2018 - 2022 ($ million)
o 4.3 Application Segment Analysis 2018 - 2022
o Exhibit 18: Historic Market Size - Application Segment 2018 - 2022 ($ million)
o 4.4 Distribution Channel Segment Analysis 2018 - 2022
o Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 20: Five forces analysis - Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 23: Threat of new entrants - Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 24: Threat of substitutes - Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 25: Threat of rivalry - Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 26: Chart on Market condition - Five forces 2023 and 2028
• 6 Market Segmentation by Product
o 6.1 Market segments
o Exhibit 27: Chart on Product - Market share 2023-2028 (%)
o Exhibit 28: Data Table on Product - Market share 2023-2028 (%)
o 6.2 Comparison by Product
o Exhibit 29: Chart on Comparison by Product
o Exhibit 30: Data Table on Comparison by Product
o 6.3 Basal insulin analog - Market size and forecast 2023-2028
o Exhibit 31: Chart on Basal insulin analog - Market size and forecast 2023-2028 ($ million)
o Exhibit 32: Data Table on Basal insulin analog - Market size and forecast 2023-2028 ($ million)
o Exhibit 33: Chart on Basal insulin analog - Year-over-year growth 2023-2028 (%)
o Exhibit 34: Data Table on Basal insulin analog - Year-over-year growth 2023-2028 (%)
o 6.4 NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028
o Exhibit 35: Chart on NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028 ($ million)
o Exhibit 36: Data Table on NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028 ($ million)
o Exhibit 37: Chart on NPH (Neutral Protamine Hagedorn) - Year-over-year growth 2023-2028 (%)
o Exhibit 38: Data Table on NPH (Neutral Protamine Hagedorn) - Year-over-year growth 2023-2028 (%)
o 6.5 Market opportunity by Product
o Exhibit 39: Market opportunity by Product ($ million)
o Exhibit 40: Data Table on Market opportunity by Product ($ million)
• 7 Market Segmentation by Application
o 7.1 Market segments
o Exhibit 41: Chart on Application - Market share 2023-2028 (%)
o Exhibit 42: Data Table on Application - Market share 2023-2028 (%)
o 7.2 Comparison by Application
o Exhibit 43: Chart on Comparison by Application
o Exhibit 44: Data Table on Comparison by Application
o 7.3 Type I diabetes - Market size and forecast 2023-2028
o Exhibit 45: Chart on Type I diabetes - Market size and forecast 2023-2028 ($ million)
o Exhibit 46: Data Table on Type I diabetes - Market size and forecast 2023-2028 ($ million)
o Exhibit 47: Chart on Type I diabetes - Year-over-year growth 2023-2028 (%)
o Exhibit 48: Data Table on Type I diabetes - Year-over-year growth 2023-2028 (%)
o 7.4 Type II diabetes - Market size and forecast 2023-2028
o Exhibit 49: Chart on Type II diabetes - Market size and forecast 2023-2028 ($ million)
o Exhibit 50: Data Table on Type II diabetes - Market size and forecast 2023-2028 ($ million)
o Exhibit 51: Chart on Type II diabetes - Year-over-year growth 2023-2028 (%)
o Exhibit 52: Data Table on Type II diabetes - Year-over-year growth 2023-2028 (%)
o 7.5 Market opportunity by Application
o Exhibit 53: Market opportunity by Application ($ million)
o Exhibit 54: Data Table on Market opportunity by Application ($ million)
• 8 Market Segmentation by Distribution Channel
o 8.1 Market segments
o Exhibit 55: Chart on Distribution Channel - Market share 2023-2028 (%)
o Exhibit 56: Data Table on Distribution Channel - Market share 2023-2028 (%)
o 8.2 Comparison by Distribution Channel
o Exhibit 57: Chart on Comparison by Distribution Channel
o Exhibit 58: Data Table on Comparison by Distribution Channel
o 8.3 Retail - Market size and forecast 2023-2028
o Exhibit 59: Chart on Retail - Market size and forecast 2023-2028 ($ million)
o Exhibit 60: Data Table on Retail - Market size and forecast 2023-2028 ($ million)
o Exhibit 61: Chart on Retail - Year-over-year growth 2023-2028 (%)
o Exhibit 62: Data Table on Retail - Year-over-year growth 2023-2028 (%)
o 8.4 Hospitals - Market size and forecast 2023-2028
o Exhibit 63: Chart on Hospitals - Market size and forecast 2023-2028 ($ million)
o Exhibit 64: Data Table on Hospitals - Market size and forecast 2023-2028 ($ million)
o Exhibit 65: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
o Exhibit 66: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
o 8.5 Market opportunity by Distribution Channel
o Exhibit 67: Market opportunity by Distribution Channel ($ million)
o Exhibit 68: Data Table on Market opportunity by Distribution Channel ($ million)
• 9 Customer Landscape
o 9.1 Customer landscape overview
o Exhibit 69: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 70: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 71: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 72: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 73: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 74: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 75: Matrix on vendor position and classification
o 12.3 Becton Dickinson and Co.
o Exhibit 76: Becton Dickinson and Co. - Overview
o Exhibit 77: Becton Dickinson and Co. - Business segments
o Exhibit 78: Becton Dickinson and Co. - Key news
o Exhibit 79: Becton Dickinson and Co. - Key offerings
o Exhibit 80: Becton Dickinson and Co. - Segment focus
o 12.4 Biocon Ltd.
o Exhibit 81: Biocon Ltd. - Overview
o Exhibit 82: Biocon Ltd. - Business segments
o Exhibit 83: Biocon Ltd. - Key offerings
o Exhibit 84: Biocon Ltd. - Segment focus
o 12.5 Biomm
o Exhibit 85: Biomm - Overview
o Exhibit 86: Biomm - Product / Service
o Exhibit 87: Biomm - Key offerings
o 12.6 Eli Lilly and Co.
o Exhibit 88: Eli Lilly and Co. - Overview
o Exhibit 89: Eli Lilly and Co. - Product / Service
o Exhibit 90: Eli Lilly and Co. - Key news
o Exhibit 91: Eli Lilly and Co. - Key offerings
o 12.7 Empreendimentos Pague Menos SA
o Exhibit 92: Empreendimentos Pague Menos SA - Overview
o Exhibit 93: Empreendimentos Pague Menos SA - Product / Service
o Exhibit 94: Empreendimentos Pague Menos SA - Key offerings
o 12.8 Gulf Pharmaceutical Industries
o Exhibit 95: Gulf Pharmaceutical Industries - Overview
o Exhibit 96: Gulf Pharmaceutical Industries - Product / Service
o Exhibit 97: Gulf Pharmaceutical Industries - Key offerings
o 12.9 MannKind Corp.
o Exhibit 98: MannKind Corp. - Overview
o Exhibit 99: MannKind Corp. - Product / Service
o Exhibit 100: MannKind Corp. - Key offerings
o 12.10 Medtronic Plc
o Exhibit 101: Medtronic Plc - Overview
o Exhibit 102: Medtronic Plc - Business segments
o Exhibit 103: Medtronic Plc - Key news
o Exhibit 104: Medtronic Plc - Key offerings
o Exhibit 105: Medtronic Plc - Segment focus
o 12.11 Merck and Co. Inc.
o Exhibit 106: Merck and Co. Inc. - Overview
o Exhibit 107: Merck and Co. Inc. - Business segments
o Exhibit 108: Merck and Co. Inc. - Key news
o Exhibit 109: Merck and Co. Inc. - Key offerings
o Exhibit 110: Merck and Co. Inc. - Segment focus
o 12.12 Novartis AG
o Exhibit 111: Novartis AG - Overview
o Exhibit 112: Novartis AG - Business segments
o Exhibit 113: Novartis AG - Key offerings
o Exhibit 114: Novartis AG - Segment focus
o 12.13 Novo Nordisk AS
o Exhibit 115: Novo Nordisk AS - Overview
o Exhibit 116: Novo Nordisk AS - Business segments
o Exhibit 117: Novo Nordisk AS - Key offerings
o Exhibit 118: Novo Nordisk AS - Segment focus
o 12.14 Sanofi SA
o Exhibit 119: Sanofi SA - Overview
o Exhibit 120: Sanofi SA - Business segments
o Exhibit 121: Sanofi SA - Key news
o Exhibit 122: Sanofi SA - Key offerings
o Exhibit 123: Sanofi SA - Segment focus
o 12.15 Wockhardt Ltd.
o Exhibit 124: Wockhardt Ltd. - Overview
o Exhibit 125: Wockhardt Ltd. - Product / Service
o Exhibit 126: Wockhardt Ltd. - Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 127: Inclusions checklist
o Exhibit 128: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 129: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 130: Research methodology
o Exhibit 131: Validation techniques employed for market sizing
o Exhibit 132: Information sources
o 13.5 List of abbreviations
o Exhibit 133: List of abbreviations


Exhibits:
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Country Market Characteristics
Exhibits4: Executive Summary - Chart on Market Segmentation by Product
Exhibits5: Executive Summary - Chart on Market Segmentation by Application
Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary - Chart on Vendor Market Positioning
Exhibits8: Parent market
Exhibits9: Market Characteristics
Exhibits10: Offerings of vendors included in the market definition
Exhibits11: Market segments
Exhibits12: Chart on Brazil - Market size and forecast 2023-2028 ($ million)
Exhibits13: Data Table on Brazil - Market size and forecast 2023-2028 ($ million)
Exhibits14: Chart on Brazil: Year-over-year growth 2023-2028 (%)
Exhibits15: Data Table on Brazil: Year-over-year growth 2023-2028 (%)
Exhibits16: Historic Market Size - Data Table on human insulin drugs market in Brazil 2018 - 2022 ($ million)
Exhibits17: Historic Market Size - Product Segment 2018 - 2022 ($ million)
Exhibits18: Historic Market Size - Application Segment 2018 - 2022 ($ million)
Exhibits19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
Exhibits20: Five forces analysis - Comparison between 2023 and 2028
Exhibits21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits23: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits24: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits25: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits26: Chart on Market condition - Five forces 2023 and 2028
Exhibits27: Chart on Product - Market share 2023-2028 (%)
Exhibits28: Data Table on Product - Market share 2023-2028 (%)
Exhibits29: Chart on Comparison by Product
Exhibits30: Data Table on Comparison by Product
Exhibits31: Chart on Basal insulin analog - Market size and forecast 2023-2028 ($ million)
Exhibits32: Data Table on Basal insulin analog - Market size and forecast 2023-2028 ($ million)
Exhibits33: Chart on Basal insulin analog - Year-over-year growth 2023-2028 (%)
Exhibits34: Data Table on Basal insulin analog - Year-over-year growth 2023-2028 (%)
Exhibits35: Chart on NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028 ($ million)
Exhibits36: Data Table on NPH (Neutral Protamine Hagedorn) - Market size and forecast 2023-2028 ($ million)
Exhibits37: Chart on NPH (Neutral Protamine Hagedorn) - Year-over-year growth 2023-2028 (%)
Exhibits38: Data Table on NPH (Neutral Protamine Hagedorn) - Year-over-year growth 2023-2028 (%)
Exhibits39: Market opportunity by Product ($ million)
Exhibits40: Data Table on Market opportunity by Product ($ million)
Exhibits41: Chart on Application - Market share 2023-2028 (%)
Exhibits42: Data Table on Application - Market share 2023-2028 (%)
Exhibits43: Chart on Comparison by Application
Exhibits44: Data Table on Comparison by Application
Exhibits45: Chart on Type I diabetes - Market size and forecast 2023-2028 ($ million)
Exhibits46: Data Table on Type I diabetes - Market size and forecast 2023-2028 ($ million)
Exhibits47: Chart on Type I diabetes - Year-over-year growth 2023-2028 (%)
Exhibits48: Data Table on Type I diabetes - Year-over-year growth 2023-2028 (%)
Exhibits49: Chart on Type II diabetes - Market size and forecast 2023-2028 ($ million)
Exhibits50: Data Table on Type II diabetes - Market size and forecast 2023-2028 ($ million)
Exhibits51: Chart on Type II diabetes - Year-over-year growth 2023-2028 (%)
Exhibits52: Data Table on Type II diabetes - Year-over-year growth 2023-2028 (%)
Exhibits53: Market opportunity by Application ($ million)
Exhibits54: Data Table on Market opportunity by Application ($ million)
Exhibits55: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits56: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits57: Chart on Comparison by Distribution Channel
Exhibits58: Data Table on Comparison by Distribution Channel
Exhibits59: Chart on Retail - Market size and forecast 2023-2028 ($ million)
Exhibits60: Data Table on Retail - Market size and forecast 2023-2028 ($ million)
Exhibits61: Chart on Retail - Year-over-year growth 2023-2028 (%)
Exhibits62: Data Table on Retail - Year-over-year growth 2023-2028 (%)
Exhibits63: Chart on Hospitals - Market size and forecast 2023-2028 ($ million)
Exhibits64: Data Table on Hospitals - Market size and forecast 2023-2028 ($ million)
Exhibits65: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
Exhibits66: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
Exhibits67: Market opportunity by Distribution Channel ($ million)
Exhibits68: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits69: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits70: Impact of drivers and challenges in 2023 and 2028
Exhibits71: Overview on Criticality of inputs and Factors of differentiation
Exhibits72: Overview on factors of disruption
Exhibits73: Impact of key risks on business
Exhibits74: Vendors covered
Exhibits75: Matrix on vendor position and classification
Exhibits76: Becton Dickinson and Co. - Overview
Exhibits77: Becton Dickinson and Co. - Business segments
Exhibits78: Becton Dickinson and Co. - Key news
Exhibits79: Becton Dickinson and Co. - Key offerings
Exhibits80: Becton Dickinson and Co. - Segment focus
Exhibits81: Biocon Ltd. - Overview
Exhibits82: Biocon Ltd. - Business segments
Exhibits83: Biocon Ltd. - Key offerings
Exhibits84: Biocon Ltd. - Segment focus
Exhibits85: Biomm - Overview
Exhibits86: Biomm - Product / Service
Exhibits87: Biomm - Key offerings
Exhibits88: Eli Lilly and Co. - Overview
Exhibits89: Eli Lilly and Co. - Product / Service
Exhibits90: Eli Lilly and Co. - Key news
Exhibits91: Eli Lilly and Co. - Key offerings
Exhibits92: Empreendimentos Pague Menos SA - Overview
Exhibits93: Empreendimentos Pague Menos SA - Product / Service
Exhibits94: Empreendimentos Pague Menos SA - Key offerings
Exhibits95: Gulf Pharmaceutical Industries - Overview
Exhibits96: Gulf Pharmaceutical Industries - Product / Service
Exhibits97: Gulf Pharmaceutical Industries - Key offerings
Exhibits98: MannKind Corp. - Overview
Exhibits99: MannKind Corp. - Product / Service
Exhibits100: MannKind Corp. - Key offerings
Exhibits101: Medtronic Plc - Overview
Exhibits102: Medtronic Plc - Business segments
Exhibits103: Medtronic Plc - Key news
Exhibits104: Medtronic Plc - Key offerings
Exhibits105: Medtronic Plc - Segment focus
Exhibits106: Merck and Co. Inc. - Overview
Exhibits107: Merck and Co. Inc. - Business segments
Exhibits108: Merck and Co. Inc. - Key news
Exhibits109: Merck and Co. Inc. - Key offerings
Exhibits110: Merck and Co. Inc. - Segment focus
Exhibits111: Novartis AG - Overview
Exhibits112: Novartis AG - Business segments
Exhibits113: Novartis AG - Key offerings
Exhibits114: Novartis AG - Segment focus
Exhibits115: Novo Nordisk AS - Overview
Exhibits116: Novo Nordisk AS - Business segments
Exhibits117: Novo Nordisk AS - Key offerings
Exhibits118: Novo Nordisk AS - Segment focus
Exhibits119: Sanofi SA - Overview
Exhibits120: Sanofi SA - Business segments
Exhibits121: Sanofi SA - Key news
Exhibits122: Sanofi SA - Key offerings
Exhibits123: Sanofi SA - Segment focus
Exhibits124: Wockhardt Ltd. - Overview
Exhibits125: Wockhardt Ltd. - Product / Service
Exhibits126: Wockhardt Ltd. - Key offerings
Exhibits127: Inclusions checklist
Exhibits128: Exclusions checklist
Exhibits129: Currency conversion rates for US$
Exhibits130: Research methodology
Exhibits131: Validation techniques employed for market sizing
Exhibits132: Information sources
Exhibits133: List of abbreviations